高胰岛素原与C肽比值可识别进展为临床诊断高风险且对替普利珠单抗治疗有反应的2型1期糖尿病个体
该事后分析基于TrialNet替普利珠单抗预防研究中63例2期1型糖尿病参与者的基线血清,检测胰岛素原与C肽比值(PI:C)。结果显示,基线PI:C升高与安慰剂组和替普利珠单抗组中更快的糖尿病进展强烈相关,但替普利珠单抗消除了治疗前高PI:C对1型糖尿病进展的影响。作者认为,PI:C比值等活动性疾病读数可能有助于识别1型糖尿病疾病修饰治疗的最佳候选者或时机。
要点
- 基线PI:C升高与安慰剂组和替普利珠单抗组中更快的糖尿病进展强烈相关。
- 替普利珠单抗消除了治疗前高PI:C对1型糖尿病进展的影响。
- 高PI:C与低PI:C个体对药物治疗的差异反应独立于替普利珠单抗对PI:C比值或相关免疫细胞的影响。
核心结论
- 治疗前高PI:C可识别出2期1型糖尿病中快速进展至3期疾病且从替普利珠单抗治疗中获益的个体。
- 这些数据提示,PI:C比值等活动性疾病读数可用于识别1型糖尿病疾病修饰治疗的最佳候选者或时机。
研究设计与样本
- 事后分析,纳入纵向TrialNet替普利珠单抗预防研究中63例2期1型糖尿病参与者的基线血清样本(替普利珠单抗组n=41,安慰剂组n=22)。
- 检测基线血清胰岛素原和C肽水平,分析完整(未加工)胰岛素原与C肽比值及其与进展至3期糖尿病的关系。
- 此外,使用先前检测的人口学、C肽、葡萄糖和胰岛素原数据进行新数据分析。
主要发现
- 基线PI:C升高与安慰剂组和替普利珠单抗组中更快的糖尿病进展强烈相关。
- 替普利珠单抗消除了治疗前高PI:C对1型糖尿病进展的影响。
- 高PI:C与低PI:C个体对药物治疗的差异反应独立于替普利珠单抗对PI:C比值或相关免疫细胞的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Tractable precision biomarkers to identify immunotherapy responders are lacking in type 1 diabetes. We hypothesised that proinsulin:C-peptide (PI:C) ratios, a readout of beta cell stress, could provide insight into type 1 diabetes progression and responses to immunotherapy. METHODS: In this post hoc analysis, proinsulin and C-peptide levels were determined in baseline serum samples from 63 participants with stage 2 type 1 diabetes in the longitudinal TrialNet Teplizumab Prevention Study (n=41 in the teplizumab arm; n=22 in the placebo arm). In addition, previously tested demographic, C-peptide, glucose and proinsulin data were used for the new data analyses. The ratio of intact (unprocessed) proinsulin to C-peptide was analysed and relationships with progression to stage 3 diabetes were investigated. RESULTS: Elevated baseline PI:C was strongly associated with more rapid progression of diabetes in both the placebo and teplizumab treatment groups, but teplizumab abrogated the impact of high pre-treatment PI:C on type 1 diabetes progression. Differential responses of drug treatment in those with high vs low PI:C ratios were independent of treatment effects of teplizumab on the PI:C ratio or on relevant immune cells. CONCLUSIONS/INTERPRETATION: High pre-treatment PI:C identified individuals with stage 2 type 1 diabetes who were exhibiting rapid progression to stage 3 disease and who displayed benefit from teplizumab treatment. These data suggest that readouts of active disease, such as PI:C ratio, could serve to identify optimal candidates or timing for type 1 diabetes disease-modifying therapies.
引用
- Sims EK, Geyer SM, Long SA, et al. High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia. 2023. PMID: 37667106. doi:10.1007/s00125-023-06003-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。